| PMC full text: | Published online 2022 Mar 3. doi: 10.1186/s12879-022-07153-4
|
Table 2
Clinical characteristics of post-COVID-19 syndrome
N =29 | |
|---|---|
| Symptoms—n (%) | |
| Fatigue | 25 (86%) |
| Muscle pain | 18 (62%) |
| Dyspnea | 14 (48%) |
| Inappropriate sinus tachycardia | 9 (31%) |
| Low-grade fever | 9 (31%) |
| Functional status | |
| Grade 0 | 0 (0%) |
| Grade I—n (%) | 7 (24%) |
| Grade II—n (%) | 8 (27.5%) |
| Grade III—n (%) | 5 (17.2%) |
| Grade IV—n (%) | 9 (31%) |
| Median number of days until evaluation days (IQR) | 57 (42–71) |
| Median number of days to extra-respiratory positive RT- PCR (IQR) | 55 (39–67) |
| SARS-CoV-2 IgG tests—n (%) | 25 (86%) |
| Hemoglobin (g/dL)—median (IQR) | 14.3 (13.2–15) |
| Lymphocyte count (×10E3/µl)—median (IQR) | 1.4 (1.2–1.7) |
| Platelet count (×10E3/µL)—median (IQR) | 202 (184–238) |
| Serum creatinine (mg/dL)—median (IQR) | 0.72 (0.63–0.82) |
| Alanin aminotransferase (U/L)—median (IQR) | 24 (20–39.5) |
| >40 U/L—n (%) | 7 (25%) |
| ≤40 U/L—n (%) | 21 (75%) |
| Ferritin (µg/L)—median (IQR) | 100 (38.5–204) |
| >205 (µg/L)—n (%) | 7 (25%) |
| ≤205 (µg/L)—n (%) | 21 (75%) |
| Positive SARS-CoV-2 RT-PCR | |
| Plasma—n (%) | 13 (44.8%) |
| Stool—n (%) | 5 (17.2%) |
| Urine—n (%) | 4 (13.7%) |
| At least one positive result—n (%) | 15 (51.7%) |
| Two positive results—n (%) | 5 (17,2%) |
| Three positive results—n (%) | 2 (6.8%) |
nnumber, IQR interquartile range